DOI: 10.1128/JCM.00480-08
Article Figures & Data
Tables
- TABLE 1.
Most common pulsed-field types among MSSA and MRSA isolates from nasal colonization studies
Methicillin status S. aureus pulsed-field type; no. (%) of isolates in: 2001 to 2002 2003 to 2004 Methicillin USA200; 92 (29.1) USA200; 59 (24.9) susceptiblea USA600; 40 (12.7) USA600; 33 (13.9) USA900; 29 (9.2) USA900; 10 (4.2) USA800; 21 (6.6) Group A; 10 (4.2) Group A; 18 (5.7) USA500; 9 (3.8) USA300; 14 (4.4) Group D; 9 (3.8) Other types; 102 (32.3) Other types; 107 (45.1) Methicillin USA100; 36 (48.0) USA100; 60 (44.8) resistantb USA800; 17 (22.7) USA800; 23 (17.2) USA700; 7 (9.3) USA300; 23 (17.2) USA300; 6 (8.0) USA400; 8 (6.0) USA1000; 2 (2.7) USA200; 6 (4.5) USA400; 1 (1.3) USA700; 3 (2.2) Other types; 6 (8) Other types; 11 (8.1) - TABLE 2.
Key MSSA resistance and toxin profiles by PFGE type
Type 2001 to 2002a 2003 to 2004b No. of isolates (n = 316) % Resistant to: %PVL+/%TSST+ No. of isolates (n = 237) % Resistant to: %PVL+/%TSST+ Erythromycin Levofloxacin Erythromycin Levofloxacin USA200 92 28.3 1.1 0/87.0 59 33.9 0 0/84.7 USA300 14 28.6 0 7.1/7.1 6 33.3 0 0/0 USA400 5 40.0 0 0/0 7 0 0 0/0 USA500 3 33.3 0 0/0 9 33.3 22.2 0/0 USA600 40 2.5 0 0/2.5 33 6.1 0 0/6.1 USA700 7 14.3 0 0/0 4 50.0 0 0/0 USA800 21 9.5 0 0/14.3 25 40.0 8.0 0/0 USA900 29 24.1 0 0/0 10 20.0 0 0/0 USA1000 7 0 0 0/0 7 28.6 0 0/0 USA1100 1 0 0 100/0 1 0 0 100/0 USA1200 6 16.7 0 0/0 9 11.1 0 0/0 Group A 18 72.2 0 0/0 10 60.0 0 0/0 Group B 10 0 0 0/0 7 14.3 0 0/0 Group C 6 16.7 0 0/0 2 0 0 0/0 Group D 11 9.1 0 0/0 9 11.1 0 0/0 Group E 4 0 0 0/0 9 0 0 0/0 - TABLE 3.
Key MRSA resistance and toxin profiles by PFGE type
Type 2001 to 2002a 2003 to 2004b No. of isolates (n = 75) No. of PFGE patterns % Resistant to: %PVL+/%TSST+ No. of isolates (n = 134) No. of PFGE patterns % Resistant to: %PVL+/%TSST+ Erythromycin Levofloxacin Erythromycin Levofloxacin USA100 36 21 94.4 91.7 0/0 60 15 100 91.7 0/0 USA200 1 1 100 100 0/100 6 5 66.7 50 0/66.7 USA300 6 3 83.3 33.3 83.3/0 23 5 91.3 34.8 87.0/0 USA400 1 1 100 0 100/0 8 3 50.0 25.0 62.5/0 USA500 1 1 0 100 0/0 0 USA600 1 1 0 0 0/0 3 3 100 100 0/0 USA700 7 3 85.7 0 0/0 3 2 33.3 0 0/0 USA800 17 6 29.4 5.9 0/17.6 23 6 52.2 4.3 0/30.4 USA1000 2 1 50 50 0/0 1 1 100 0 0/0 USA1100 0 1 1 100 0 0/0 Iberian 1 1 100 100 0/0 0 - TABLE 4.
Antimicrobial susceptibility profiles for MSSA and MRSA isolates
Antimicrobial agent No. of susceptible isolates (%) among: MSSA in: MRSA in: 2001 to 2002 (n = 316) 2003 to 2004 (n = 237) 2001 to 2002 (n = 75) 2003 to 2004 (n = 134) Chloramphenicol 273 (86.4) 197 (83.1) 49 (65.3) 69 (51.9) Clindamycina 316 (100) 232 (97.9) 51 (68.0) 88 (66.4) Clindamycinb 263 (83.2) 184 (77.6) 34 (45.0) 50 (37.6) Erythromycin 250 (79.1) 180 (76.0) 19 (25.3) 24 (18.1) Gentamicin 315 (99.7) 236 (99.6) 75 (100) 12 (99.3) Levofloxacin 315 (99.7) 233 (98.3) 34 (45.3) 60 (45.1) Linezolid 316 (100) 237 (100) 75 (100) 133 (100) Penicillin 39 (12.3) 27 (11.4) 0 (0) 0 (0) Oxacillin 316 (100) 237 (100) 0 (0) 0 (0) Quinupristin-Dalfopristin 301 (100) 237 (100) 75 (100) 133 (100) Rifampin 316 (100) 237 (100) 74 (98.7) 131 (98.5) Tetracycline 306 (96.8) 230 (97.0) 69 (92.0) 122 (91.7) Trimethoprim- sulfamethoxazole 316 (100) 235 (99.2) 75 (100) 133 (100) Vancomycin 316 (100) 237 (100) 75 (100) 133 (100)
